Sign in

    Samantha Meadows-Ortiz

    Research Analyst at BMO Capital Markets

    Samantha Meadows-Ortiz is an equity research analyst at BMO Capital Markets, focusing on the biotechnology and pharmaceutical sectors with specialization in clinical-stage drug development analysis. She covers companies advancing late-stage clinical trials, providing detailed insights on the strategic rationale and progress of Phase III studies for firms such as those pursuing novel oncology and immunology therapies. While specific third-party rankings and historical performance metrics are not publicly available, her sector research is regularly cited in institutional investment discussions and industry events. Meadows-Ortiz has been with BMO Capital Markets since at least early 2025, and her professional credentials include securities industry licensure and active FINRA registration.

    Samantha Meadows-Ortiz's questions to Revolution Medicines (RVMD) leadership

    Samantha Meadows-Ortiz's questions to Revolution Medicines (RVMD) leadership • Q4 2024

    Question

    Samantha Meadows-Ortiz of BMO Capital Markets inquired about the strategic rationale for advancing two Phase III studies in earlier-line pancreatic ductal adenocarcinoma (PDAC), specifically the company's conviction in the adjuvant setting and the role of RAS mutations.

    Answer

    CEO Dr. Mark Goldsmith explained that strong monotherapy data in PDAC provides the conviction to pursue all lines of therapy, including first-line and adjuvant settings. He stated that the proof-of-concept from later-line data supports moving into the adjuvant space. Dr. Goldsmith also clarified there is no evidence that RAS mutation frequency differs in earlier-stage disease compared to advanced cancer, as it is the primary driver in nearly all PDAC cases.

    Ask Fintool Equity Research AI